InvestorsHub Logo
Followers 271
Posts 15407
Boards Moderated 1
Alias Born 03/28/2013

Re: None

Wednesday, 07/13/2016 10:19:07 AM

Wednesday, July 13, 2016 10:19:07 AM

Post# of 461361
“With Anavex drug candidates targeting the sigma-1 receptor, and with the mechanism of action being further validated, we are even more encouraged to advance our studies with additional neurodegenerative diseases,” said Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex. “The Company is intrigued to realize the direct link to the body’s endocannabinoid system and to proceed with potential studies with our sigma-1 drugs candidates and cannabinoids.”

$AVXL
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News